Drug Trial Radar · NCT02481830
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
569
Actual
Start
Sep 14, 2015
Primary completion
Aug 17, 2018
Study completion Aug 30, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Jun 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Conditions
- Lung Cancer
Interventions
NivolumabDrug
TopotecanDrug
AmrubicinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: OS was followed continuously while participants were on the study drug and every 3 months, minimum follow up for overall survival was 15.8 months
Locations
151 sites in 25 countries. Site status is shown where the registry gives one.
Local Institution - 0065
Little Rock, Arkansas
Local Institution - 0024
New Haven, Connecticut
Local Institution - 0018
Atlanta, Georgia
Local Institution - 0056
St Louis, Missouri
Local Institution - 0088
Lincoln, Nebraska
Local Institution - 0173
Johnson City, New York
Local Institution - 0001
Durham, North Carolina
Local Institution - 0090
Cleveland, Ohio
Local Institution - 0002
Bethlehem, Pennsylvania
Local Institution - 0057
Lancaster, Pennsylvania
Local Institution - 0053
Philadelphia, Pennsylvania
Local Institution - 0089
Nashville, Tennessee
Local Institution - 0009
Nashville, Tennessee
Local Institution - 0070
Kennewick, Washington
Local Institution - 0027
Murdoch, Australia
Local Institution - 0102
Waratah, New South Wales, Australia
Local Institution - 0030
Brisbane, Queensland, Australia
Local Institution - 0031
Elizabeth Vale, South Australia, Australia
Local Institution - 0103
Kurralta Park, South Australia, Australia
Local Institution - 0028
Perth, Western Australia, Australia
Local Institution - 0085
Graz, Austria
Local Institution - 0086
Vienna, Austria
Local Institution - 0084
Wels, Austria
Local Institution - 0013
Brussels, Belgium
Local Institution - 0012
Edegem, Belgium
Local Institution - 0011
Leuven, Belgium
Local Institution - 0010
Yvoir, Belgium
Local Institution - 0099
São Paulo, Brazil
Local Institution - 0095
Ijuí, Rio Grande do Sul, Brazil
Local Institution - 0094
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0093
Barretos, São Paulo, Brazil
Local Institution - 0025
Recoleta, Santiago de Chile, Chile
Local Institution - 0201
Beijing, China
Local Institution - 0198
Guangzhou, China
Local Institution - 0182
Hangzhou, China
Local Institution - 0192
Shanghai, China
Local Institution - 0200
Beijing, Beijing Municipality, China
Local Institution - 0199
Beijing, Beijing Municipality, China
Local Institution - 0188
Beijing, Beijing Municipality, China
Local Institution - 0190
Beijing, Beijing Municipality, China
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.